CAR-T for Gastric Cancer: Why an American Patient Traveled to China

By SinoCareLink Team · Published: 2 November 2026 · Last updated: 2 November 2026

Disclosure: SinoCareLink coordinates medical travel to China, including cancer treatment, and works with hospitals in Shenzhen, including HKU-Shenzhen Hospital. SinoCareLink was not involved in this patient's treatment; this article is based on public reports.

In June 2026, China approved the world's first CAR-T cell therapy for solid tumors — a Claudin18.2-targeted treatment for advanced gastric and gastroesophageal junction (GEJ) cancer that is not yet available in the United States or anywhere else in the West. Within months, an American patient traveled to China to receive it: Larry, from Los Angeles, who had exhausted multiple lines of treatment at home. He and his wife Jamie flew more than 11,600 kilometers to Shenzhen, where he received the newly approved CAR-T therapy at the International Medical Center of HKU-Shenzhen Hospital. At early follow-up, the hospital reported that his CA19-9 tumor marker had fallen from about 8,200 U/mL before the infusion to 57.6 U/mL, with marked tumor shrinkage. One patient's early response does not predict how others will respond, and long-term outcomes are not yet known. Their story is a window into how far China's medical innovation has come.

An 11,600-Kilometer Journey: Larry's Story

Running Out of Options in the United States

Larry was diagnosed with moderately-to-poorly differentiated adenocarcinoma of the gastroesophageal junction about a year and a half before arriving in Shenzhen. Over that time, he had been through multiple lines of standard treatment in the US: neoadjuvant therapy, surgery, first-line and second-line regimens, paclitaxel combined with ramucirumab, and even intraperitoneal paclitaxel perfusion. The cancer kept progressing.

His situation was exceptionally difficult. GEJ cancer with peritoneal metastasis is among the most refractory cancer types — published literature reports a median survival of only 3 to 6 months. During his earlier treatment, his CA19-9 tumor marker had climbed to 1,455 U/mL. In July 2026, he tried zolbetuximab (a monoclonal antibody targeting Claudin18.2) combined with chemotherapy — and the disease progressed again. By the time of his CAR-T infusion, his CA19-9 had risen to about 8,200 U/mL.

The Keyword That Pointed to China

The lead came from Larry's wife, Jamie. Instead of searching only for "gastric cancer," she combined her husband's biomarker with his diagnosis — and searched for Claudin18.2.

His wife says she had long known about the Claudin 18.2 biomarker, but only realized its importance when she searched for it online — the search that led them to China.

A biopsy of Larry's peritoneal metastasis confirmed the match: Claudin18.2 expression of 2+/3+, with 99% of tumor cells positive.

What Is Claudin18.2 CAR-T Therapy?

CAR-T (chimeric antigen receptor T-cell) therapy reprograms a patient's own immune cells to hunt cancer. Doctors collect T-cells from the patient's blood, engineer them in a laboratory to carry a receptor that recognizes a specific target — in this case, the Claudin18.2 protein found on the surface of many gastric and pancreatic cancer cells — multiply them, and infuse them back into the patient.

Professor Pan Hongming, Vice President of HKU-Shenzhen Hospital and a professor at its Oncology Medical Center, likens the modified cells to "retrained special forces" (translated from Chinese) equipped with a "navigation probe" that lets them actively find and kill cancer cells expressing the target. Unlike chemotherapy, which is cleared from the body as it metabolizes, CAR-T cells can continue to multiply and provide ongoing immune surveillance — which is why, in principle, a single infusion may be enough — although some patients receive more than one infusion.

Until recently, approved CAR-T therapies only worked against blood cancers such as leukemia and lymphoma. Solid tumors — which account for the vast majority of cancers — remained the unsolved frontier of the field.

A World First, Made in China

On June 22, 2026, China's National Medical Products Administration (NMPA) approved satricabtagene autoleucel (satri-cel, CT041), developed by CARsgen Therapeutics — making it the world's first CAR-T cell therapy approved for a solid tumor. It has not been approved by the US FDA or the European Medicines Agency. It is indicated for patients with CLDN18.2-positive, HER2-negative advanced gastric or GEJ adenocarcinoma whose disease has progressed after at least two prior lines of therapy. (Shanghai Pudong Government announcement)

The approval rests on the confirmatory Phase II trial CT041-ST-01 (ClinicalTrials.gov: NCT04581473), led by Professor Shen Lin of Peking University Cancer Hospital across 24 clinical centers. Published in The Lancet (doi:10.1016/S0140-6736(25)00860-8) and presented at the ASCO 2025 annual meeting, the trial showed that satri-cel significantly extended median progression-free survival versus the physician's choice of standard later-line therapy (3.25 vs. 1.77 months; HR 0.37, P<0.0001). Median overall survival was 7.92 vs. 5.49 months (HR 0.693), a trend toward improvement rather than a statistically significant difference. (Beijing Cancer Hospital summary)

The milestone reflects a broader shift. Shanghai's Pudong district alone is home to five approved CAR-T products — about a quarter of the global total, according to the Pudong government. CARsgen describes the approval as a shift from "following" to "leading" in cell therapy. For patients like Larry — whose cancer had progressed through chemotherapy, immunotherapy, anti-angiogenic therapy, and even Claudin18.2 antibody therapy — the only approved CAR-T option for solid tumors is currently in China.

Treatment at HKU-Shenzhen Hospital International Medical Center

Larry received his treatment at the International Medical Center of HKU-Shenzhen Hospital, a public hospital in Shenzhen's Greater Bay Area that operates dedicated services for international patients. (Shenzhen Health Commission report)

On September 29, 2026, Larry's CAR-T cells were infused back into his body. As expected with cell therapy, he developed manageable side effects — fever peaking at 39°C, mild-to-moderate swelling in both legs, and a slight drop in blood pressure. The medical team responded promptly with fluids and tocilizumab, the standard agent for cytokine release syndrome (CRS), and monitored him closely throughout. About ten days after infusion, all adverse-reaction indicators had stabilized.

Professor Pan emphasizes two principles for this therapy:

• Target matching is essential. This therapy is not suitable for all gastric cancer patients. Pathology testing must confirm Claudin18.2 expression, and a multidisciplinary team must evaluate the patient's condition, treatment history, and risks before proceeding.
• Safety management matters. CAR-T therapy can cause fever and cytokine release syndrome. It is performed only in medical institutions with the experience and facilities to monitor and manage these reactions.

Early Follow-Up Results

Follow-up testing after the infusion showed:

• CA19-9 tumor marker: from about 8,200 U/mL just before the infusion to 57.6 U/mL at early follow-up
• Imaging showed marked tumor shrinkage, which the hospital described as "approaching complete remission" (接近完全缓解) at early follow-up. No formal response assessment or long-term follow-up has been published.

This is one patient's early result. Responses to CAR-T therapy vary widely, many patients do not respond, and serious side effects can occur.

Professor Pan described the approval of a solid-tumor CAR-T product in China as an important advance for patients with digestive-tract cancers who have exhausted other options and whose tumors match the target. Larry has since been discharged from hospital; continued follow-up will show how durable his response is. His journey was first reported by People magazine before treatment began, and the hospital's account of his treatment was published by the Shenzhen Health Commission (source).

What Larry's Journey Says About Medicine in China

Illustrative view of Futian District, Shenzhen (2016). Not taken during the patient's visit; it does not show the hospital where he was treated. Photo: "Shenzhen Skyline from Futian District2" by Huangdan2060, via Wikimedia Commons, licensed under CC BY 3.0.

A decade ago, the idea of an American flying to China for a treatment unavailable at home would have seemed improbable. Today, Larry's journey illustrates a new reality:

1. China is originating, not just adopting, frontier therapies. The world's first approved solid-tumor CAR-T was developed by a Chinese company, tested in a Chinese-led randomized trial published in The Lancet, and approved by Chinese regulators — before any Western agency.
2. Some Chinese hospitals now serve international patients. HKU-Shenzhen Hospital, for example, has an International Medical Center, and its team described the close monitoring and side-effect management used in this case.
3. Access timelines differ between countries. When a therapy is approved in one country before another, some patients with limited options will consider traveling for it — after weighing cost, risks, and the evidence with their own doctors.

Frequently Asked Questions

Is CAR-T therapy for solid tumors available in the United States?

Not yet. As of late 2026, no CAR-T therapy for solid tumors has been approved by the US FDA. Satri-cel received FDA Regenerative Medicine Advanced Therapy (RMAT) designation in 2022, and a North American Phase 1b/2 trial (NCT04404595) is listed as active but no longer recruiting. There is currently no FDA-approved route to this therapy in the US; patients should check ClinicalTrials.gov or ask their oncologist about other CLDN18.2 trials.

Why was the world's first solid-tumor CAR-T approved in China?

China has invested heavily in cell and gene therapy over the past decade, building an integrated ecosystem of research hospitals, biotech companies, and manufacturing capacity. Satri-cel received Breakthrough Therapy Designation from China's drug evaluation center in March 2025 and was reviewed under a priority pathway, based on a randomized Phase II trial that met its primary endpoint (progression-free survival).

Who is eligible for Claudin18.2 CAR-T therapy?

The approved indication covers patients with CLDN18.2-positive, HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma that has progressed after at least two prior lines of therapy. Final eligibility requires pathology confirmation and a multidisciplinary assessment.

What are the side effects of CAR-T therapy?

The most common is cytokine release syndrome (CRS) — fever, low blood pressure, and swelling — which occurred in about 95% of trial patients but is generally manageable with established protocols (such as tocilizumab) in experienced centers. Severe (grade 3 or higher) drops in blood counts were very common in the trial.

Can international patients receive treatment in Chinese hospitals?

Yes. Some Chinese hospitals, such as HKU-Shenzhen Hospital, have international medical centers for overseas patients. Eligibility for any specific treatment is decided by the treating team after reviewing medical records.

Conclusion: What One Case Can and Cannot Tell Us

Eleven thousand six hundred kilometers. One biomarker keyword. One newly approved therapy. Larry's story shows how quickly cell therapy for solid tumors is moving in China, where the first CAR-T product for a solid tumor has now been approved. Whether this early response lasts — and how such therapies compare over the long term — will be answered by further follow-up and research.

Related reading

• Gastric cancer CAR-T in China: eligibility and documents
• GI cancer tumor markers explained: CEA, CA 19-9 and AFP
• Cancer screening in China: PET-CT, tumor markers and early detection

Sources

• Shenzhen Health Commission, "From Los Angeles to Shenzhen" (hospital account, 29 October 2026): https://wjw.sz.gov.cn/wzx/content/post_13044631.html
• Shanghai Pudong Government, approval announcement (24 June 2026): https://english.pudong.gov.cn/2026-06/24/c_1192878.htm
• Peking University Cancer Hospital, CT041-ST-01 trial summary: https://www.bjcancer.org.cn/Html/News/Articles/1001248.html
• ClinicalTrials.gov, NCT04581473 (CT041-ST-01): https://clinicaltrials.gov/study/NCT04581473
• ClinicalTrials.gov, NCT04404595 (North American Phase 1b/2): https://clinicaltrials.gov/study/NCT04404595
• Qi C, et al. The Lancet, 2025 (CT041-ST-01). doi:10.1016/S0140-6736(25)00860-8

About SinoCareLink: SinoCareLink is an inbound medical services company connecting international clients with China's leading healthcare resources. We follow and share developments at the frontier of Chinese medicine.

Disclaimer: This article is for general information only and is not medical advice. It describes one patient's early response as reported by the treating hospital; individual results vary, and serious side effects are possible. Satri-cel is not approved by the US FDA. Treatment decisions should be made with qualified physicians.